// App-Quantinova.ai

425 : Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.

Researchers

Presenter

  • Li-Tzong Chen

Principal Investigators

  • Jens T Siveke

  • Andrea Wang-Gillam

  • Richard Hubner

  • Shubham Pant

  • Tomislav Dragovich

  • Vincent M. Chung

  • David Z. Chang

  • Paul J. Ross

  • Prasad Cooray

  • Niall C. Tebbutt

  • Fabio A. Franke

  • Bruce Belanger

  • Navreet Dhindsa

  • Floris De Jong

  • Khalid Mamlouk

  • Daniel D. Von Hoff

Medical Centers

  • National Health Research Institutes (NHRI) - National Institute of Cancer Research, Taipei, Taiwan

  • Klinikum rechts der Isar der TU Muenchen, Munich, Germany

  • Washington University in St Louis, St. Louis, MO

  • Christie Hospital NHS Foundation Trust, Altrincham, United Kingdom

  • Oklahoma University Medical Center, Oklahoma City, OK

  • Banner MD Anderson Cancer Center, Mesa, AZ

  • City of Hope, Duarte, CA

  • Virginia Oncology Associates - Hampton, Newport News, VA

  • Guy's Hospital, London, United Kingdom

  • Box Hill Hospital, Heidelberg, Australia

  • Olivia Newton-John Cancer and Wellness Centre, ÃÂ,Ã, Heidelberg Repatriation Hospital, Heidelberg, Australia

  • Hospital de Caridade de Ijui Avenida David Jose Martins, Ijui-RS, Brazil

  • Merrimack Pharmaceuticals, Cambridge, MA

  • Baxalta, Neuchâtel, Switzerland

  • TGen, Banner Health, Phoenix, Scottsdale, AZ

Locations

  • Taiwan

  • Germany

  • United States

  • United Kingdom

  • Australia

  • Brazil

  • Switzerland

Companies

  • Merrimack Pharmaceut

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Carbohydrate antigen 19-9

Drug/Treatment

  • 5-fluorouracil + leucovorin

  • Gemcitabine

  • leucovorin

  • Irinotecan sucrosofate

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01494506

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved